Abstract
Background Data on the rate and severity of reinfections with SARS-CoV-2 in real-world settings are scarce and the effects of booster vaccination on reinfection risk are unknown.
Methods In a retrospective cohort study, all SARS-CoV-2 laboratory-confirmed residents of Vojvodina, registered in the database of the Institute of Public Health of Vojvodina, between March 6, 2020 and October 31, 2021, were followed for reinfection ≥90 days after primary infection. Data were censored at the end of follow-up (January 31, 2022) or death. The risk of reinfection was visualized with Kaplan-Meier plots. To examine whether vaccination protected from reinfection, the subset of Vojvodina residents with primary infection in 2020 (March 6–December 31) were matched (1:2) with controls without reinfection.
Results Until January 31, 2022, 13,792 reinfections were recorded among 251,104 COVID-19 primary infections (5·49%). Most reinfections (86·8%) were recorded in January 2022. Reinfections were mostly mild (99·2%). Hospitalizations were uncommon (1·08% vs. 3·70% in primary infection) and COVID-19 deaths were very rare (n=20, case fatality rate 0·15%). The overall incidence rate of SARS-CoV-2 reinfections was 5·99 (95% CI 5·89-6·09) per 1,000 person-months for those who survived the first three months after primary infection. The reinfection risk was estimated as 0·76% at six months, 1·36% at nine months, 4·96% at 12 months, 16·7% at 15 months, and 18·9% at 18 months. Among 34 second reinfections, none resulted in hospitalization or death. Unvaccinated (OR=1·23; 95%CI=1·14–1·33), incompletely (OR=1·33; 95%CI=1·08–1·64) or completely vaccinated (OR=1·50; 95%CI=1·37–1·63), were modestly more likely to be reinfected compared with those who received a third (booster) vaccine dose.
Conclusions SARS-CoV-2 reinfections were exceptionally uncommon until the end of 2021 but became common with the advent of the Omicron variant. Very few reinfections were severe. A vaccination booster dose may modestly reduce reinfection risk.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of Institute of Public Health of Vojvodina waived ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
